BARCELONA, Spain — The JAK inhibitor upadacitinib can effectively treat systemic sclerosis-associated interstitial lung disease (SSc-ILD), according to results from a new clinical trial ...

MONDAY, Dec. 23, 2024 (HealthDay News) -- For patients with ulcerative colitis, upadacitinib is associated with improved ...

Key Takeaways. Upadacitinib, a JAK1 inhibitor, is effective for inflammatory conditions but may induce alopecia areata in some patients. A case study reported alopecia areata in a patient after ...

New post-hoc analysis demonstrated efficacy of RINVOQ ® (upadacitinib) in moderate-to-severe atopic dermatitis patients with varying degrees of severity in head and neck involvement, with results ...

Upadacitinib inhibits two JAK-dependent cytokines, interleukin 6 and interferon gamma, which have been implicated in the pathogenesis of GCA. The latter could be particularly important, Blockmans ...

Upadacitinib, a Janus kinase (JAK) inhibitor, is currently marketed under the brand name Rinvoq for patients aged 12 years and older with refractory, moderate to severe atopic dermatitis whose ...

At 5 days, 16.7% of patients on upadacitinib compared with 9.2% of patients on placebo experienced a reduction in symptoms (P ≤.01), and results were continually improving through day 15.

Upadacitinib, a Janus kinase (JAK) inhibitor, is currently marketed under the brand name Rinvoq for patients aged 12 years and older with refractory, moderate to severe atopic dermatitis whose ...

In the upadacitinib 15mg arm, fewer patients experienced at least 1 disease flare through week 52 compared with the placebo arm (34% vs 56%, respectively; P =.0014).

On August 10 2023, the China National Intellectual Property Administration (CNIPA) issued two invalidation decisions, No. 561725 (Decision #1) and No. 562232 (Decision #2), in response to invalidity ...